News & Updates
Filter by Specialty:
Bimekizumab safe, effective in moderate-to-severe plaque psoriasis
The high clinical response levels achieved with bimekizumab over 48 weeks persist up to week 96 in patients with moderate-to-severe plaque psoriasis, results of the BE RADIANT phase IIIb trial have shown. In addition, those on secukinumab who switched to bimekizumab have achieved similar responses at 96 weeks.
Bimekizumab safe, effective in moderate-to-severe plaque psoriasis
18 Sep 2023
Long-term hydrochlorothiazide use ups risk of skin cancer
Using hydrochlorothiazide (HCTZ) for longer durations and in higher cumulative doses increases the risks for keratinocyte carcinoma and melanoma, reveals a study.
Long-term hydrochlorothiazide use ups risk of skin cancer
17 Aug 2023
Abrocitinib effectively controls AD regardless of dosing regimen
In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.
